Disease · MONDO_0001209

common wart

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. common wart. Diseases, record MONDO_0001209. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001209

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: common wart; Open Targets
Open Targets ID: MONDO_0001209; Open Targets
Other names: verruca vulgaris; Open Targets
Disease Ontology: DOID:11165; Disease Ontology
MeSH: D014860; MeSH
NCI Thesaurus: C27087; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 25 drugs, from DailyMed and TTD; Open Targets

Drugs25

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SALICYLIC ACID	CHEMBL424	Small molecule	Approval	DailyMed	6	2	2	Drugs and targets
PODOFILOX	CHEMBL61	Small molecule	Approval	TTD	1	0	0	Drugs and targets
HYDROGEN PEROXIDE	CHEMBL71595	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
CANTHARIDIN	CHEMBL48449	Small molecule	Phase 3	ClinicalTrials.gov	5	4	4	Drugs and targets
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	CHEMBL6068359	Vaccine component	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
FUROSEMIDE	CHEMBL35	Small molecule	Phase 3	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
TUBERCULIN	CHEMBL2108161		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
VEHICLE	CHEMBL2108661		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RESIQUIMOD	CHEMBL383322	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
CIDOFOVIR	CHEMBL5314375	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 25

See all 25 drugs

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Unknown	https://conductscience.org/library/genes/7421	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Unknown	https://conductscience.org/library/genes/1719	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Unknown	https://conductscience.org/library/genes/2908	Drugs and targets
SLC12A1	Solute carrier family 12 member 1	1	Sodium-(potassium)-chloride cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6557	Drugs and targets
TLR7	Toll-like receptor 7	1	Toll-like receptor 7 agonist	Phase 2	https://conductscience.org/library/genes/51284	Drugs and targets
TLR8	Toll-like receptor 8	1	Toll-like receptor 8 agonist	Phase 2	https://conductscience.org/library/genes/51311	Drugs and targets

Trials37

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03687372	Study of A-101 Topical Solution for the Treatment of Common Warts	Phase 3	503	2020-10-05	Common Wart	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT03691831	A Study of A-101 Topical Solution for the Treatment of Common Warts	Phase 3	502	2020-10-05	Common Wart	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT02971891	A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts	Phase 3	484	2023-09-14	Cutaneous Common Warts	FUROSEMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03812510	Safety Study of A-101 Topical Solution for the Treatment of Common Warts	Phase 3	426	2020-11-23	Common Wart	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT03278028	A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts	Phase 2	159	2019-03-29	Common Wart	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT03210337	A Phase2 of A-101 Topical Solution in Subjects With Common Warts	Phase 2	157	2019-05-01	Common Wart	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT02669862	A Study of A-101 Solution in Subjects With Common Warts.	Phase 2	98	2018-12-07	Common Warts	HYDROGEN PEROXIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04428359	A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts	Not applicable	66	2021-04-09	Verruca Viral	CHOLECALCIFEROL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03487549	Cantharidin and Occlusion in Verruca Epithelium	Phase 2	56	2021-09-01	Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca	CANTHARIDIN	Its record names the disease	ClinicalTrials.gov
NCT07246590	Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)	Phase 3	302		Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts	CANTHARIDIN, VEHICLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 37

See all 37 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Active vs Vehicle: deaths from any cause	0 of 254	0 of 249	503	NCT03687372	Trial comparisons
Active vs Vehicle: serious adverse events	1 of 254	1 of 249	503	NCT03687372	Trial comparisons
Active vs Vehicle: deaths from any cause	0 of 251	0 of 251	502	NCT03691831	Trial comparisons
Active vs Vehicle: serious adverse events	1 of 251	2 of 251	502	NCT03691831	Trial comparisons
CLS006 (Furosemide) vs Vehicle: deaths from any cause	0 of 246	0 of 238	484	NCT02971891	Trial comparisons
CLS006 (Furosemide) vs Vehicle: serious adverse events	0 of 246	0 of 238	484	NCT02971891	Trial comparisons
A-101 45% (Active) vs Isopropyl Alcohol and Water (Vehicle): Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts	70 of 163	116 of 213	376	NCT03812510	Trial comparisons
Hydrogen Peroxide 45% A-101 vs Isopropyl Alcohol and Water Vehicle: Number of Subjects With a Single Wart at Baseline Whose Wart Was Clear on the PWA Scale Between Active and Vehicle Group (PWA=0) at Visit 10 (Day 60)	33 of 162	10 of 141	303	NCT03687372	Trial comparisons
Active vs Vehicle: Number of Subjects With a Single Wart at Baseline Whose Wart Was Clear on the PWA Scale Between Active and Vehicle Group (PWA=0) at Visit 10 (Day 60)	19 of 126	4 of 142	268	NCT03691831	Trial comparisons
Active vs Vehicle: deaths from any cause	0 of 81	0 of 78	159	NCT03278028	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials20

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30920098	RESULT	1	PubMed
30775294	RESULT	1	PubMed
30623542	RESULT	1	PubMed
30447324	RESULT	1	PubMed
30003983	RESULT	1	PubMed
28852295	RESULT	1	PubMed
28384048	RESULT	1	PubMed
27730031	RESULT	1	PubMed
26294740	RESULT	1	PubMed
25070525	RESULT	1	PubMed

1 to 10 of 20

See all 20 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001209

GET https://conductscience.org/api/diseases/v1/MONDO_0001209/drugs?page=2

API reference For AI assistants